Search company, investor...

Lead Therapeutics

leadtherapeutics.com

Founded Year

2006

Stage

Unattributed | Alive

Total Raised

$20M

Last Raised

$3M | 14 yrs ago

About Lead Therapeutics

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule pre-IND candidates against clinically validated therapeutic targets by leveraging the best of the US and China. Headquartered in the San Francisco Bay Area, LEAD Therapeutics is led by an experienced small molecule drug discovery team with proven track records in the pharmaceutical and biotech industries. The company plans to carry out the majority of its discovery research activities in China.

Headquarters Location

999 Bayhill Drive Suite 130

San Bruno, California, 94066,

United States

650-737-1630

Missing: Lead Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lead Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lead Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lead Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Lead Therapeutics Patents

Lead Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Amines
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/12/2017

Dietary supplements, Food additives, Drug discovery, Pharmaceutical industry, Nanoparticles

Application

Application Date

12/12/2017

Grant Date

Title

Related Topics

Dietary supplements, Food additives, Drug discovery, Pharmaceutical industry, Nanoparticles

Status

Application

Latest Lead Therapeutics News

Head hunter Russell Reynolds adds health care head in San Francisco office, social media guru in Palo Alto

May 21, 2013

Russell Reynolds Associates, a New York-based executive search firm, named Sofie Qiao as San Francisco-based executive director of the health care sector. Prior to joining Russell Reynolds, Qiao co-founded biotech firm LEAD Therapeutics, consulted and did other management work at Discovery Partners International, Syrrx \(now Takeda California\), McKinsey & Co., and Genzyme \(now Sanofi\). She’s also a member of BayHelix, an “invitation-only” organization of Chinese business leaders in the global…

Lead Therapeutics Frequently Asked Questions (FAQ)

  • When was Lead Therapeutics founded?

    Lead Therapeutics was founded in 2006.

  • Where is Lead Therapeutics's headquarters?

    Lead Therapeutics's headquarters is located at 999 Bayhill Drive, San Bruno.

  • What is Lead Therapeutics's latest funding round?

    Lead Therapeutics's latest funding round is Unattributed.

  • How much did Lead Therapeutics raise?

    Lead Therapeutics raised a total of $20M.

  • Who are the investors of Lead Therapeutics?

    Investors of Lead Therapeutics include Mustang Ventures, Pappas Ventures and ProQuest Investments.

  • Who are Lead Therapeutics's competitors?

    Competitors of Lead Therapeutics include Forma Therapeutics, MicuRx Pharmaceuticals, CellCentric, Kalexsyn, CytoBioscience, Floragenex, BioFocus, Astex Pharmaceuticals (acquired by SuperGen), InVasc Therapeutics, Caprion Pharmaceuticals and 14 more.

Compare Lead Therapeutics to Competitors

P
Priaxon

Priaxon is a research company focusing on drug discovery for small molecule therapeutics.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

M
MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.

A
Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

CellCentric Logo
CellCentric

CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.